AzTrials
AzTrials

Monitoring, PhysiologicLYNG21NCT05117606

LYNG21: Ably LYNG Clinical Demonstration in Operative Environment

A study testing LYNG by Ably Medical in people with Monitoring, Physiologic, run by Ably Medical AS at 1 site in Norway.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study main objective will be to compare measurements of heart rate, respiration rate, blood pressure and movement done by LYNG by Ably Medical with the corresponding measurements made by standard equipment in a patient sample in a hospital setting. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Monitoring, Physiologic
What is being tested?
LYNG by Ably Medical
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteNorway
Study dates
25 May 2021to 31 Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • For patients:
  • Admitted to hospital,
  • Able to provide voluntary, informed consent.

Who cannot join

  • For patients:
  • Health condition that endangers patient by participation due to pain, rehabilitation, and/or negative impact on treatment or care, as evaluated by medical personnel,
  • Pregnancy,
  • Significantly reduced mobility that implies substantial strain for moving in and out of bed, as evaluated by medical personnel
  • Unable to provide informed, voluntary consent personally or by legal guardian, * below 18 years old,
  • Patients with implantable devices such as pacemakers, baclofen pumps, insulin pumps, etc, or
  • Any way identified as 'vulnerable'
  • The nurse handing recruitment will explicitly check for inclusion/exclusion criteria alignment and document this in the study Enrolment Form. The routine will be to check for formal criteria and to describe the study in such a manner that the patient understands content, and make sure the patient understands before consenting

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Helse Møre og Romsdal HF - Aalesund Sjukehus

    Ålesund, 6026

Other trials in Norway

About this study

Official title: ABLY LYNG Study at Helse More Romsdal - Aalesund Sykehus HMR With the Ably LYNG Patient Care Solution Advanced Prototype by Ably Medical AS.

The study main objective will be to compare measurements of heart rate, respiration rate, blood pressure and movement done by LYNG by Ably Medical with the corresponding measurements made by standard equipment in a patient sample in a hospital setting. The comparison will show the degree of agreement between LYNG and the existing current standard equipment. Data from the study will support Ably Medical in optimizing the LYNG product and measurement precision.

Read the detailed description

The LYNG sensor mat is placed beneath a regular bed matrass and captures data without direct patient contact. Data collected by the LYNG sensor is transmitted via cables to the bed-side connectivity box for initial local analysis and storage. Data will be extracted and formatted for post-analysis in additional software for verification and validation purposes.

Specifically, the LYNG study objectives are as follows:

  1. collect sensor data from LYNG Solution to optimize the LYNG data algorithms to further improve parameter estimations of patient heart rate, respiratory rate, blood pressure and movement indicators.
  2. Compare parameter estimation by LYNG against current and relevant standard of care measurement methods

The study design is a within-subjects comparison in parameter estimation with Ably LYNG as comparator to standard of care. Patients will take part in 60-minute sessions where measurements are collected in accidence to standard procedure for the standard equipment while the LYNG system collects the same data non- intrusively. The data will not be part of any clinical decision making or have any impact of the patient care. The study will take place during Q2-Q3/2021 with estimated 8-12 weeks duration including logistics, setup, data collection, study closure.

Being tested
LYNG by Ably Medical
Keywords
non-intrusive monitoring

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LYNG by Ably MedicalDevice

    Comparing LYNG to traditional, standard equipment for heart rate, respiration, movement, and blood pressure.

Study groups in NCT05117606
Study groupRoleWhat they receive
VitalsignsOtherData from patients (heart rate, respiration, movement, blood pressure) is measured with traditional, standard hospital equipment in parallell with data from LYNG mat captured non-intrusively in the same session.
Receives: Device: LYNG by Ably Medical

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Absolute Relative Error of Heart Rate (beats per minute)

    absolute relative error = (reference measure/LYNG measure)/Reference

    Measured: 60 minutes

  2. Absolute Relative Error of Respiration Rate (respirations per minute)

    absolute relative error = (reference measure/LYNG measure)/Reference

    Measured: 60 minutes

  3. Movement

    Comparison of movement as part of patient instruction compared to indications of movement in movement sensors. Qualitative analysis.

    Measured: 60 minutes

  4. absolute relative error of Blood Pressure = (reference measure/LYNG measure)/Reference

    absolute relative error = (reference measure/LYNG measure)/Reference

    Sphygmomanometer, millimeters of mercury (mmHg) upper (systolic), lower (diastolic), and mean value.

    Measured: 60 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Nov 2021
  2. Study start25 May 2021
  3. Primary completion1 Dec 2021 (estimated)
  4. Study completion31 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
Within subject comparison - of two screening methodologies (standard equipment with direct patient sensors vs LYNG contactless sensors). The number patients in the study is chosen to have a broad view on patients population found in a general hospital setting, for example a range of height, weight, gender, age.
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05117606
Sponsor's protocol ID
LYNG21_AALESUND
Acronym
LYNG21
Status last verified
Oct 2021
First submitted
14 Sep 2021
Last updated
11 Nov 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing LYNG by Ably Medical in people with Monitoring, Physiologic, run by Ably Medical AS at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Absolute Relative Error of Heart Rate (beats per minute) (time frame: 60 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in